Lake Street Rates Vivani Medical (VANI) buy, $4 Price Target
Lake Street has reiterated its buy rating on Vivani Medical with a price target of $4, a 231.95% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Lake Street rated Vivani Medical, Inc. ($VANI) "buy" with a $4 price target on June 23, 2026.
Since the rating, $VANI is up 4.2% after 1 week, up 16.8% after 1 month and down 5.9% to date (from the $1.19 close on Jun 23, 2026).
VANI
Vivani Medical, Inc.
Key Points
- Lake Street reiterated its buy rating for Vivani Medical, Inc. (VANI) on June 23, 2026, with a price target of $4.
- Lake Street's $4 price target implies 231.95% upside from Vivani Medical, Inc.'s ($VANI) current $1.21 share price.
- Vivani Medical shares traded at $1.18 on Tuesday, with a market cap of $97.4 million and a 52-week range of $0.92 to $1.92.
- Insider Gregg Williams made multiple stock purchases, and analysts' consensus rating remains strong buy with a mean target of $3.75.
Get $VANI trade alerts by text
We text you when insiders, Congress or big funds trade $VANI. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Vivani Medical, Inc. alert may contain errors. Disclosures
Lake Street reiterated its buy rating for Vivani Medical, Inc. (NasdaqCM: VANI) on June 23, 2026. Analyst Thomas Flaten set a price target of $4, reinforcing confidence in the company's future prospects.
Vivani Medical, Inc. Stock Up 1.3%
Shares of NasdaqCM:VANI traded near $1.18 on Tuesday. Vivani Medical, Inc. has a market cap of approximately $97.4 million. The company has a beta of 3.289, indicating higher volatility compared to the market. The stock's 52-week range is between $0.92 and $1.92, with a 50-day moving average of $1.23 and a 200-day moving average of $1.31. The company's current ratio stands at 3.181, with a quick ratio of 3.018 and a debt-to-equity ratio of 95.756.
$VANI price target
Vivani Medical, Inc. daily closes and this analyst's $4 target. Not advice.
Insider Buying and Selling at Vivani Medical, Inc.
Insider Gregg Williams has been actively purchasing shares of Vivani Medical. On June 15, 2026, Williams bought 1,587,301 shares at an average price of $1.26. He made similar purchases on May 15 and April 15, 2026, each time buying the same number of shares at the same price.
Analysts Set New Price Targets
On June 23, 2026, Lake Street reiterated its buy rating for Vivani Medical with a price target of $4. Previously, on April 1, 2026, HC Wainwright & Co. maintained a buy rating with a target of $3.5. The overall analyst consensus for Vivani Medical is a strong buy, with a mean target price of $3.75 based on two analyst opinions.
About Vivani Medical
Vivani Medical, Inc., headquartered in Alameda, California, is a clinical-stage biopharmaceutical company. It focuses on developing miniaturized and subdermal drug implants using its NanoPortal technology. The company aims to improve clinical outcomes in chronic disease treatment. Its product pipeline includes drug implants for chronic weight management and diabetes treatment, with applications in both humans and companion animals. Dr. Adam Mendelsohn, Ph.D., serves as the CEO, leading a team of 42 employees.
Bottom Line
Vivani Medical, Inc. continues to attract attention from analysts and insiders alike. Lake Street's reiterated buy rating and $4 price target highlight ongoing confidence in the company's potential. Investors should note that these ratings are based on past data and may not reflect current market conditions.
Related Filing Alerts
Source: Lake Street's rating change on $VANI (Jun 23, 2026). Written by software, not financial advice. How we make alerts